Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
ARROWHEAD PHRMCT RG (NQ: ARWR)
13.73 USD  +2.66 (+24.03%)
Official Closing Price  /  Updated: 8:00 PM EDT, Jun 18, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 5,610,604
Open 11.68
Bid (Size) 13.76 (900)
Ask (Size) 13.92 (1000)
Prev. Close 11.07
Today's Range 11.43 - 14.00
52wk Range 1.480 - 14.00
Shares Outstanding 87,577,188
Dividend Yield N/A
Performance
YTD
+269.09%
+269.09%
1 Month
+40.53%
+40.53%
3 Month
+91.49%
+91.49%
6 Month
+325.08%
+325.08%
1 Year
+732.12%
+732.12%
Top News
More News
Arrowhead Completes Enrollment in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Arrowhead Pharmaceuticals completed enrollment of a Phase 1 clinical study of ARO-AAT for treatment of alpha-1 antitrypsin deficiency Read More
from Business Wire News Releases
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Read More
from Business Wire News Releases
More News
Read More
Arrowhead Completes Enrollment in Single Dose Portion of Phase 1/2 Study of ARO-HBV
from Business Wire News Releases
Arrowhead Pharmaceuticals to Present at Upcoming June 2018 Conferences
from Business Wire News Releases
Arrowhead Pharmaceuticals Presents New Preclinical Data on ARO-ENaC for Treatment of Cystic Fibrosis
from Business Wire News Releases
Arrowhead Pharma Trading Higher Today on Above-Average Volume, Consistent With Trend (ARWR)
from Comtex SmarTrend® News Briefs
ARWR Crosses Above Average Analyst Target
category ETFs
from ETF Channel
Arrowhead Doses First Hepatitis B Patients in Multiple Dose Portion of Phase 1/2 Study of ARO-HBV
from Business Wire News Releases
Why Arrowhead Pharmaceuticals Stock Is Skyrocketing 23.3% Today
category Market News , ARWR
from Motley Fool
Arrowhead Pharmaceuticals Presents Preclinical Data on Expanding Cardiometabolic Pipeline
from Business Wire News Releases
Arrowhead Pharma Crosses Below its 10-day MA (ARWR)
from Comtex SmarTrend® News Briefs
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.